The clinically meaningful improvement in ORR and PFS was confirmed recently in the CITYSCAPE study (a phase II study of tiragolumab plus atezolizumab vs placebo plus atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC) (324). Here, CD274 is linked to non-small cell lung carcinoma.